台灣泌尿科醫學會E-School

台灣泌尿科醫學會E-School

(ME1-1) Challenging situations in robot-assisted partial nephrectomy_呂育全

2022-08-31 • 觀看: 14 • 回應: 0 • ppt
(IS6-2) Dual I-O combinations in first-line metastatic renal cell carcinoma_蘇柏榮

2022-08-31 • 觀看: 7 • 回應: 0 • ppt
(IS6-1) I-O/TKI combinations in first-line metastatic renal cell carcinoma_魏子鈞

2022-08-31 • 觀看: 10 • 回應: 0 • ppt
(IS5-1) Complications of PCNL : Risk factors and management PCNL的風險防控_石宏仁

2022-08-31 • 觀看: 13 • 回應: 0 • ppt
(IS4-3) Novel treatments of different subtypes of interstitial cystitis/ bladder pain syndrome – medical, intravesical treatment, surgery_張嘉峰

2022-08-31 • 觀看: 14 • 回應: 0 • ppt
(IS4-2) Pathophysiology of IC/BPS and potential urinary biomarkers for diagnosis_阮雍順

2022-08-31 • 觀看: 15 • 回應: 0 • ppt
(IS4-1) Current classification and differential diagnosis of interstitial cystitis/ bladder pain syndrome – based on clinical symptoms, urodynamic tests, and histological study_蒙恩

2022-08-31 • 觀看: 17 • 回應: 0 • ppt
(IS3-2) Risk of metabolic and cardiovascular adverse events with NHA among men with advanced prostate cancer_陳毓騏

2022-08-31 • 觀看: 10 • 回應: 0 • ppt
IS3-1_陳忠信

2022-08-31 • 觀看: 10 • 回應: 0 • ppt
(LS4-1) Myths about bone-targeted therapy: Optimal strategy for incorporating BTAs into treatment paradigms for PCa_洪健華

2022-08-31 • 觀看: 23 • 回應: 0 • ppt
(IS2-1) Under the spotlight: Recent updates on FGFR in urothelial carcinoma_陳忠信

2022-08-31 • 觀看: 13 • 回應: 0 • ppt
(IS1-1) How to implement precision therapies for prostate cancer in clinical practice？ _蘇柏榮

2022-08-31 • 觀看: 15 • 回應: 0 • ppt

Prev
336
337
338
339
340
341
342
343
344
345
Next
/ 1052